What is Nektar Therapeutics's preferred stock?

Nektar Therapeutics (NKTR) reported preferred stock of $0 in Q1 2026.

What does preferred stock mean?

Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.

Nektar Therapeutics NKTR Preferred Stock

Preferred Stock at other companies

Iovance Biotherapeutics, Inc.IOVA

$0—

IncyteINCY

$0—

Kymera TherapeuticsKYMR

$0—

Monte Rosa Therapeutics, Inc.GLUE

$0—

Protagonist TherapeuticsPTGX

$0—

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.25B+1,531%

Enterprise value$2.33B+874%

P/S40.5×+38.9×

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's preferred stock?: Nektar Therapeutics (NKTR) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?: Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.